Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

In this online program experts discuss best practices and emerging strategies in CAR T-cell therapy for patients with leukemia lymphoma and myeloma. Watch the on-demand Webcast download the slides from a dynamic CCO symposium in Orlando and read expert commentaries to learn more about how to integrate CAR T-cells into your clinical practice.

Share

Program Content

No activities added yet

Activities

Using CAR T-Cell Therapy
My Experience With CAR T-Cell Therapy: Key Considerations
Case Challenge
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 17, 2019

Expires: October 15, 2020

ASH 2019: CAR T-Cells
ASH 2019 Preview: Key Studies in CAR T-Cell Therapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2019

Expires: December 02, 2020

FAQ: CAR T-Cell Therapy
Frequently Asked Questions About CAR T-Cell Therapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2020

Expires: March 23, 2021

Activities

CAR T: ALL
CAR T-Cell Therapy for ALL: Maximizing Outcomes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

CAR T: Lymphomas
Most Recent and Promising Advances in CAR T-Cell Therapy for B-Cell NHL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

CAR T: Myeloma
The Future of CAR T-Cell Therapy for Myeloma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

CAR T: Managing Toxicities
Optimizing Outcomes: Identifying and Managing CAR T-Cell–Mediated Toxicities
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2019

Expires: December 04, 2020

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Celgene

Kite A GILEAD Company